General
Preferred name
SULFACETAMIDE
Synonyms
Sulfacetamide (sodium monohydrate) ()
Sulfacetamide144-80-9 ()
Sulphacetamide ()
Acetosulfamine ()
Klaron ()
Sulster ()
SULF-15 ()
SULF-10 ()
Sulfair-15 ()
Bleph-30 ()
Sulfacetamide (Triple Sulfa) ()
Urosulfon ()
Sulfacel-15 ()
Cetamide ()
FML-S ()
Bleph-10 ()
Ocusulf-30 ()
NSC-63871 ()
Sulten-10 ()
Ocusulf-10 ()
Triple sulfa (sulfacetamide) ()
Sulfacetamidum ()
P&D ID
PD001751
CAS
144-80-9
127-56-0
6209-17-2
Tags
natural product
drug
available
Approved by
FDA
First approval
1945
Drug Status
approved
Drug indication
Antibacterial
Acne vulgaris
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Sulfacetamide is a sulfonamide antibiotic with bacteriostatic actions and broad-spectrum activity against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
DESCRIPTION
Sulfacetamide is a sulfonamide antibacterial compound that has been in clinical use since the 1940s . It inhibits the bacterial dihydropteroate synthase pathway which generates the folic acid that is essential for bacterial growth.
(GtoPdb)
DESCRIPTION
Sulfacetamide is a sulfonamide antibiotic as a dihydropteroate Synthase inhibitor. It is a competitive inhibitor of bacterial para-aminobenzoic acid, which is required for bacterial synthesis of folic acid. Sulfacetamide is used for the treatment of skin infections and urinary tract infections. It is also used to treat acne and seborrheic dermatitis.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
22
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
48
Molecular Weight
214.04
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
1
cLogP
0.09
TPSA
89.26
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.68
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Bacterial
antibiotic
Pathway
Anti-infection
Indication
conjunctivitis
MOA
PABA antagonist
Therapeutic Class
Antibiotics
Solubility
DMSO (Slightly), Methanol (Slightly)
Source data
